Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal

HONG KONG, Nov. 6, 2026 /PRNewswire/ -- On 5 November 2026, Hong Kong Economic Journal (HKEJ), one of Hong Kong's most influential Chinese financial publications, hosted the "ESG & Sustainability Awards of Excellence 2026" ceremony. At the event, Fosun International received the "ESG & Corporate Sustainability Excellence Award", recognizing its remarkable achievements and strong market standing in advancing environmental, social, and governance (ESG) practices as well as sustainability.

HKEJ pointed out that the Government of the Hong Kong Special Administrative Region officially released the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026–2030) this year, setting out a range of key green development and environmental protection targets. The government, business community, financial institutions, and all sectors of society are working together to advance Hong Kong's green transition. Many well-known companies in Hong Kong, including Fosun International, have long been committed to promoting ESG practices. Their efforts hold significant strategic importance in reinforcing Hong Kong's position as an international financial center. The awards were established to recognize companies that have made outstanding contributions to advancing sustainability. In addition to Fosun International, other recipients of the awards include Henderson Land Development, China Overseas Land & Investment, FWD Life Insurance, Bank of China (Hong Kong), China Minsheng Bank Hong Kong Branch, etc.

Advancing climate commitments to achieve notable recognition for ESG performance

HKEJ highlighted that global investors have attached increasing importance to the ESG performance of enterprises in recent years, while Fosun International has continued to advance its ESG efforts, achieving remarkable results. To date, Fosun International's MSCI ESG Rating has been upgraded to the highest rating of AAA. It has been included in the S&P Global Sustainability Yearbook 2026 and also named among the Top 1% in the S&P Global Sustainability Yearbook (China Edition) 2026 for the third consecutive year. Its Hang Seng Sustainability Rating has been upgraded from AA- to AA+. It has also been selected as a constituent of the Hang Seng Corporate Sustainability Benchmark Index for the seventh consecutive year and included as a constituent of the Hang Seng ESG 50 Index. Additionally, Fosun International's FTSE Russell ESG score has consistently been higher than the global industry average and it has remained a constituent of the FTSE4Good Index Series for five consecutive years.

To address climate change, Fosun actively responds to the national "dual carbon" goals by promoting carbon neutrality and energy conservation and emission reduction. In 2021, Fosun made a commitment to society – "strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050". Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement. In April 2026, Fosun International proactively aligned with the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and the International Financial Reporting Standards S2 Climate-related Disclosures Requirements (IFRS S2) by releasing its fourth Climate Information Disclosures Report, further enhancing the transparency of its climate initiatives and underscoring its commitment to continuous progress in environmental stewardship.

Leveraging innovation to deliver lasting social impact

Fosun adheres to an innovation-driven strategy, continuously delivering innovative achievements across its businesses to better serve society. Among which, Fosun's independently developed HANSIZHUANG became the world's first and only anti-PD-1 monoclonal antibody approved for the perioperative treatment of gastric cancer, pioneering a postoperative "chemo-sparing" regimen. HLX43, a core asset in the innovative pipeline, is a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC. It has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. FUMAINING (luvoxmetinib tablets) was approved for the treatment of pediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases.

Fosun remains committed to global cooperation and shared success, striving to make medical technologies more accessible and affordable to more patients. Yi Kai Da, China's first CAR-T cell therapy product, has been used to treat more than 1,500 patients to date, while the marketing application of Fosun's second CAR-T product, brexucabtagene autoleucel, has been accepted for review. The first da Vinci 5, the next-generation surgical system, was installed in Hong Kong SAR, and has been admitted into the Special Review Procedure for Innovative Medical Devices by the National Medical Products Administration (NMPA). The Ion Robotic Bronchoscopy (Ion System) has been successfully approved for launch and commercialization in Chinese mainland.

In global public health, as of 30 June 2026, Fosun Pharma had cumulatively supplied more than 460 million vials of artesunate for injection worldwide, saving more than 92 million patients with severe malaria.

Committed to business for good, actively giving back to society

In order to better promote the fulfillment and implementation of corporate social responsibility, Fosun Foundation was established in 2012. It has been making unremitting efforts in areas such as global emergency relief, rural revitalization, health, education, culture and art, youth development, to create social value. Of which, since its launch at the end of 2017, Fosun Foundation's Rural Doctors Program has covered 78 counties in 16 provinces, cities, and autonomous regions, supporting 25,000 rural doctors and benefiting 3 million rural families.

In support of youth entrepreneurship and development, Fosun and Fosun Foundation, together with Portuguese insurance group Fidelidade and Portugal's healthcare group Luz Saúde (Peruvian insurer La Positiva joined in 2026), launched the Protechting Open Innovation Program in early 2016. On 16 September this year, the first stop of the China Roadshow Series for the eighth edition of the Protechting Open Innovation Program (Protechting 8.0), was held at Hong Kong Science Park. Ten innovation and technology teams from Portugal, Denmark, Brazil and beyond presented their innovations, marking the highest number of participating teams since the program's inception. As of now, Protechting has engaged young entrepreneurs from more than 50 countries and regions, facilitated the incubation of over 50 pilot projects, and supported several youth-led ventures in scaling up.

Looking ahead, Fosun will continue to strengthen its core operations, drive innovation, and deepen its globalization strategy. By joining hands with customers, partners, investors, and society, Fosun remains steadfast in its original aspiration of "Contribution to Society", actively advancing global ESG sustainability to fulfill its mission of "Creating happier lives for families worldwide".

SOURCE Fosun